BLFS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioLife Solutions Inc (BLFS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising fundamentals and analyst support, the lack of immediate positive trading signals, insider selling, and declining financial performance metrics suggest that waiting for a better entry point might be prudent.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is neutral at 52.853, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading close to its pivot level of 19.201, with resistance at 20.198 and support at 18.204. This suggests limited immediate upside potential.
Analyst Carl Byrnes reiterates BLFS as a 'Top Pick 2026' and highlights its biopreservation media platform as the standard in cell and gene therapy. Analysts expect a 17%-20% YoY revenue growth in FY26, reinforcing durable growth.
Insider selling has increased significantly by 3291.23% over the last month, which could indicate a lack of confidence from insiders. Additionally, financial performance in Q4 2025 shows declining net income (-11.15% YoY), EPS (-14.81% YoY), and gross margin (-9.61% YoY).
In Q4 2025, revenue increased by 24.34% YoY to $18.785M, but net income dropped by 11.15% YoY to $11.07M. EPS decreased by 14.81% YoY to 0.23, and gross margin declined by 9.61% YoY to 63.76%.
Northland analysts have reiterated BLFS as a 'Top Pick 2026' with a price target raised to $34 from $31. They emphasize the company's structural integration into large pharma and biotech programs, viewing the recent pullback as a buying opportunity.
